Aethlon Medical Inc. (AEMD)
0.37
-0.03 (-7.75%)
At close: Mar 28, 2025, 3:56 PM
0.39
6.53%
After-hours: Mar 28, 2025, 05:31 PM EDT
-7.75% (1D)
| Bid | 0.36 |
| Market Cap | 7.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.14M |
| EPS (ttm) | -1.52 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | -0.9 |
| Analyst | Buy |
| Ask | 0.39 |
| Volume | 161,739 |
| Avg. Volume (20D) | 1,048,783 |
| Open | 0.41 |
| Previous Close | 0.40 |
| Day's Range | 0.36 - 0.41 |
| 52-Week Range | 0.24 - 1.79 |
| Beta | 1.81 |
About AEMD
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc....
Industry Medical - Devices
Sector Healthcare
IPO Date Mar 4, 1999
Employees 14
Stock Exchange NASDAQ
Ticker Symbol AEMD
Website https://www.aethlonmedical.com
Analyst Forecast
According to 1 analyst ratings, the average rating for AEMD stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 1798.05% from the latest price.
Stock Forecasts1 month ago
+18.96%
Aethlon Medical shares are trading higher after th...
Unlock content with
Pro Subscription
3 months ago
+33.83%
Aethlon Medical shares are trading higher after the company highlighted Hemopurifier's 99% in vitro capture of the H5N1 bird flu virus.
